# Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

> **NCT06393374** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1530 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** Sacituzumab tirumotecan
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06393374
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-24
- **Primary completion:** 2030-12-16
- **Final completion:** 2037-12-14
- **Target enrollment:** 1530 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393374, "Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06393374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*